635 related articles for article (PubMed ID: 16395396)
1. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.
Grosser T; Fries S; FitzGerald GA
J Clin Invest; 2006 Jan; 116(1):4-15. PubMed ID: 16395396
[TBL] [Abstract][Full Text] [Related]
2. The pharmacology of selective inhibition of COX-2.
Grosser T
Thromb Haemost; 2006 Oct; 96(4):393-400. PubMed ID: 17003913
[TBL] [Abstract][Full Text] [Related]
3. The cardiovascular pharmacology of COX-2 inhibition.
Fries S; Grosser T
Hematology Am Soc Hematol Educ Program; 2005; ():445-51. PubMed ID: 16304418
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective.
Patrono C
Br J Clin Pharmacol; 2016 Oct; 82(4):957-64. PubMed ID: 27317138
[TBL] [Abstract][Full Text] [Related]
5. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond.
Rao P; Knaus EE
J Pharm Pharm Sci; 2008 Sep; 11(2):81s-110s. PubMed ID: 19203472
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular complications of non-steroidal anti-inflammatory drugs.
Fosslien E
Ann Clin Lab Sci; 2005; 35(4):347-85. PubMed ID: 16254252
[TBL] [Abstract][Full Text] [Related]
7. Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease.
Wang M; Song WL; Cheng Y; Fitzgerald GA
J Intern Med; 2008 May; 263(5):500-5. PubMed ID: 18410593
[TBL] [Abstract][Full Text] [Related]
8. Current perspective on the cardiovascular effects of coxibs.
Konstam MA; Weir MR
Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293
[TBL] [Abstract][Full Text] [Related]
9. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
10. NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population.
Capone ML; Tacconelli S; Rodriguez LG; Patrignani P
Pharmacol Rep; 2010; 62(3):530-5. PubMed ID: 20631418
[TBL] [Abstract][Full Text] [Related]
11. Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives.
Bruno A; Tacconelli S; Patrignani P
Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):56-63. PubMed ID: 23953622
[TBL] [Abstract][Full Text] [Related]
12. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
13. Adverse effects of COX-2 inhibitors.
Sharma JN; Jawad NM
ScientificWorldJournal; 2005 Aug; 5():629-45. PubMed ID: 16113940
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function.
Cheng Y; Wang M; Yu Y; Lawson J; Funk CD; Fitzgerald GA
J Clin Invest; 2006 May; 116(5):1391-9. PubMed ID: 16614756
[TBL] [Abstract][Full Text] [Related]
15. Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process.
Vuolteenaho K; Moilanen T; Moilanen E
Basic Clin Pharmacol Toxicol; 2008 Jan; 102(1):10-4. PubMed ID: 17973900
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2, Asymmetric Dimethylarginine, and the Cardiovascular Hazard From Nonsteroidal Anti-Inflammatory Drugs.
Ricciotti E; Castro C; Tang SY; Briggs WTE; West JA; Malik D; Rhoades SD; Meng H; Li X; Lahens NF; Sparks JA; Karlson EW; Weljie AM; Griffin JL; FitzGerald GA
Circulation; 2018 Nov; 138(21):2367-2378. PubMed ID: 29930022
[TBL] [Abstract][Full Text] [Related]
17. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
Moyad MA
Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
[TBL] [Abstract][Full Text] [Related]
18. Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.
Tacconelli S; Bruno A; Grande R; Ballerini P; Patrignani P
Expert Opin Drug Saf; 2017 Jul; 16(7):791-807. PubMed ID: 28569569
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs.
Giuliano F; Warner TD
Br J Pharmacol; 1999 Apr; 126(8):1824-30. PubMed ID: 10372826
[TBL] [Abstract][Full Text] [Related]
20. Anti-inflammatory drugs in the 21st century.
Rainsford KD
Subcell Biochem; 2007; 42():3-27. PubMed ID: 17612044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
